ArticleProstate international2023

Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer.

Taketo Kawai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.